Janney Montgomery Scott LLC Grows Position in Zynex, Inc. (NASDAQ:ZYXI)

Janney Montgomery Scott LLC boosted its holdings in shares of Zynex, Inc. (NASDAQ:ZYXI) by 22.3% during the third quarter, Holdings Channel.com reports. The firm owned 144,439 shares of the company’s stock after acquiring an additional 26,368 shares during the period. Janney Montgomery Scott LLC’s holdings in Zynex were worth $1,179,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Millennium Management LLC grew its holdings in shares of Zynex by 66.5% in the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after purchasing an additional 118,615 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Zynex by 68.7% in the 2nd quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after buying an additional 77,300 shares in the last quarter. WINTON GROUP Ltd boosted its holdings in shares of Zynex by 147.6% in the 2nd quarter. WINTON GROUP Ltd now owns 36,841 shares of the company’s stock valued at $343,000 after buying an additional 21,960 shares in the last quarter. Platte River Wealth Advisors LLC raised its position in shares of Zynex by 200.0% in the 2nd quarter. Platte River Wealth Advisors LLC now owns 30,000 shares of the company’s stock valued at $280,000 after purchasing an additional 20,000 shares during the last quarter. Finally, BOKF NA purchased a new position in shares of Zynex in the 1st quarter valued at approximately $246,000. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Zynex Stock Down 3.6 %

NASDAQ ZYXI opened at $7.80 on Friday. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The business’s fifty day simple moving average is $8.23 and its 200-day simple moving average is $8.91. The firm has a market cap of $248.40 million, a PE ratio of 53.00 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings data on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. Zynex’s revenue was up .1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. As a group, equities analysts anticipate that Zynex, Inc. will post 0.2 earnings per share for the current year.

Insider Transactions at Zynex

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $8.59, for a total value of $85,900.00. Following the completion of the transaction, the chief financial officer now directly owns 44,878 shares of the company’s stock, valued at $385,502.02. This represents a 18.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 24,000 shares of company stock valued at $208,440. 52.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on ZYXI shares. Royal Bank of Canada decreased their price objective on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright raised their price objective on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.